Thomas Borody

Topelia Australia launches US$25M Series A call for COVID-19 ATT Ziverdox

Retrieved on: 
Thursday, October 14, 2021
Program, Quarantine, Thomas Borody, TGA, Disease, Australian government debt, Compliance, Government, Brain, Marketing, USD, FDA, ATT, Ulcerative colitis, Patent, Research, Clinical, COVID-19, Pharmaceutical industry, Network equipment

- Based on current research, the ATT provides an inexpensive and medically efficacious treatment for the prevention and early treatment of COVID-19.

Key Points: 
  • - Based on current research, the ATT provides an inexpensive and medically efficacious treatment for the prevention and early treatment of COVID-19.
  • The company said: "Topelia proposes to offer the ATT treatment alongside the current vaccination program to treat and vaccinate our way out of this pandemic.
  • The novel Antiviral Triple Therapy, to be branded as Ziverdox, comprises TGA-approved medications prescribed for decades with exceptional safety profiles.
  • Topelia Australia was founded based on the wealth of experience in commercialising the ground-breaking triple therapy cure for peptic ulcers which has saved over 18 thousand lives in Australia alone.